Targeting neurodegenerative diseases using risuteganib


Dr Glenn J. Jaffe, professor of ophthalmology, Dr Robert Machemer, Distinguished Professor of Ophthalmology, Chief, Division of Retinal Ophthalmology at the Duke University School of Medicine, discusses the key points of his virtual presentation," Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells (Allegro)," including targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised and the need for newer treatment therapies to target different pathways.

See more ARVO content

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.